TIGIT interacts with different ligands, including CD155 expressed on dendritic cells, thereby inhibiting tumor killing by NK cells and antigen presentation by dendritic cells, thus weakening the anti-tumor effect of T cells (14). Here, PVR is linked to neoplasm.